• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023

    5/4/23 8:30:00 AM ET
    $SRGA
    Industrial Specialties
    Health Care
    Get the next $SRGA alert in real time by email

    DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023.

    Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available on Surgalign's website for one month following the call.

    About Surgalign Holdings, Inc.

    Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation across the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company is building technologies physicians and other health providers will look to for what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign markets products throughout the United States and in approximately 50 countries worldwide through an expanding network of top independent distributors. Surgalign is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn, Twitter and Instagram.

    Forward Looking Statements

    This press release contains forward-looking statements based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management, and such forward-looking statements include (among others) statements regarding anticipated future financial and operating performance (including forecasted full-year revenue and number of HOLO sites secured), product rationalization and expense reduction initiatives and the results thereof, potential third party financing and anticipated cash needs. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including general economic conditions, as well as those within the Company's industry, and numerous other factors and risks identified in the Company's most recent Form 10-K, 10-Q and other filings with the SEC. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the Company's access to adequate operating cash flow, trade credit, borrowed funds and equity capital to fund its operations and pay its obligations as they become due, and the terms on which external financing may be available, including the impact of adverse trends or disruption in the global credit and equity markets; (ii) risks relating to existing or potential litigation or regulatory actions; (iii) the identification of control deficiencies, including material weaknesses in internal control over financial reporting; (iv) general worldwide economic conditions and related uncertainties; (v) the continued impact of the COVID-19 and the Company's attempts at mitigation, particularly in international markets served by the Company; (vi) the failure by the Company to identify, develop and successfully implement its strategic initiatives, particularly with respect to its digital surgery strategy; (vii) the reliability of our supply chain; (viii) our ability to meet obligations, including purchase minimums, under our vendor and other agreements; (ix) whether or when the demand for procedures involving our products will increase; (x) our financial position and results, total revenue, product revenue, gross margin, and operations; (xi) failure to realize, or unexpected costs in seeking to realize, the expected benefits of the Holo Surgical Inc. ("Holo Surgical") and Inteneural Networks Inc. ("INN") acquisitions, including the failure of Holo Surgical's and INN's products and services to be satisfactorily developed or achieve applicable regulatory approvals or as a result of the failure to commercialize and distribute its products; (xii) the failure to effectively integrate Holo Surgical's and INN's operations with those of the Company, including: retention of key personnel; the effect on relationships with customers, suppliers, and other third parties; and the diversion of management time and attention to the integration; (xiii) the number of shares and amount of cash that will be required in connection with any post-closing milestone payments, including as a result of changes in the trading price of the Company's common stock and their effect on the amount of cash needed by the Company to fund any post-closing milestone payments in connection with the acquisitions; (xiv) the continuation of recent quality issues with respect to our global supply chain; (xv) the effect and timing of changes in laws or in governmental regulations; and (xvi) other risks described in our public filings with the SEC. These factors should be considered carefully, and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company's SEC filings may be obtained by contacting the Company or the SEC or by visiting Surgalign's website at http://www.surgalign.com/ or the SEC's website at http://www.sec.gov/. We undertake no obligation to update these forward-looking statements except as may be required by law.

    Investor Relations and Media Relations Contact:

    Glenn Wiener

    Email: [email protected]

    Tel: +1 917 887 8434



    Primary Logo

    Get the next $SRGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRGA

    DatePrice TargetRatingAnalyst
    9/28/2021$1.50Buy → Hold
    Craig Hallum
    More analyst ratings

    $SRGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Lyle David covered exercise/tax liability with 1,329 shares, decreasing direct ownership by 2% to 83,307 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      9/18/23 11:47:26 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form 4: Amoruso Paolo covered exercise/tax liability with 2,191 shares, decreasing direct ownership by 7% to 28,809 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      9/5/23 10:20:10 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form 4: Thunander Christopher covered exercise/tax liability with 2,295 shares, decreasing direct ownership by 8% to 26,039 units

      4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)

      8/16/23 5:36:00 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    SEC Filings

    See more

    $SRGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 15-12G filed by Surgalign Holdings Inc.

      15-12G - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      11/13/23 4:08:28 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Surgalign Holdings Inc.

      EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      10/10/23 12:15:07 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Surgalign Holdings Inc.

      EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)

      10/10/23 12:15:09 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Surgalign Holdings Inc. (Amendment)

      SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/14/24 2:57:21 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Surgalign Holdings Inc.

      SC 13G - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/14/23 1:32:27 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Surgalign Holdings Inc. (Amendment)

      SC 13D/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)

      2/4/22 3:09:26 PM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing

      DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code, the Company's securities will be delisted from The Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. As previously announced, Surgalign entered into an asset purchase agreement to

      6/23/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy Code

      DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) ("Surgalign" or the "Company") a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. ("Xtant") for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain o

      6/20/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education Resources

      Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery ("ISASS") and Medical Education Resources. This three-day event will take place June 1-3, 2023 at the Marriott Marquis in San Francisco, CA. The International Society for the Advancement of Spine Surgery i

      5/23/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care

    $SRGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary

      DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022. Commenting on today's appointment, Terry Rich, President and Chief Executive Officer of Surgalign stated, "Paolo has been an invaluable member of our team since taking on the role of Interim General Counsel just a few months ago. He has quickly immersed

      8/4/22 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Announces Appointment of David Lyle as Chief Financial Officer

      DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA) ("Surgalign"), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. "David brings a wealth of experience in helping to guide the growth of technologies to Surgalign at an important and exciting inflection point of the company's evolution," said Terry Rich, Surgalign's president and chief executive officer. "David is joining Surgalign at a critical time as we transition to the early commercial stage of our HOLO AI technology platform, w

      3/7/22 9:00:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Anika Appoints Sheryl Conley to Board of Directors

      BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management

      11/1/21 9:00:00 AM ET
      $ANIK
      $SRGA
      $STIM
      Medical/Dental Instruments
      Health Care
      Industrial Specialties

    $SRGA
    Financials

    Live finance-specific insights

    See more

    $SRGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Surgalign Schedules First Quarter 2023 Earnings Release for May 11, 2023

      DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available

      5/4/23 8:30:00 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million

      Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, Mont. and DEERFIELD, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, and Surgalign Holdings, Inc., (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered

      3/1/23 9:15:00 AM ET
      $SRGA
      $XTNT
      Industrial Specialties
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Surgalign Announces Third Quarter 2022 Results and Provides Update on Business Operations and Financial Outlook

      DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022. 2022 Third Quarter Corporate Highlights: Two new clinical sites in Ohio utilize the HOLO PortalTM surgical guidance system.FDA 510(k) clearance of the Cortera™ Spinal Fixation System, the first organically designed product by Surgalign.Expansion of the Fortilink® product portfolio with TiPlus™ technology products.Settlements with Resolve Surgical Technologies and RTI Surgical, Inc., and with

      11/2/22 4:01:00 PM ET
      $SRGA
      Industrial Specialties
      Health Care
    • Surgalign Holdings downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50

      9/28/21 7:57:45 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • BTIG Research initiated coverage on Surgalign Holdings with a new price target

      BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00

      2/3/21 7:33:38 AM ET
      $SRGA
      Industrial Specialties
      Health Care
    • BTIG Research initiated coverage on Surgalign

      BTIG Research initiated coverage of Surgalign with a rating of Buy

      2/3/21 7:28:58 AM ET
      $SRGA
      Industrial Specialties
      Health Care